Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen

Sponsor

Azienda Sanitaria Ospedaliera (Other)

Overall Status

Terminated

CT.gov ID

NCT00320229

Collaborator

Cardiologia 2 - Emodinamica - Ospedale Maggiore, Novara, Italy (Other)

Enrollment

Location

Duration (Months)

12.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The aim of our study was to demonstrate that, during a percutaneous coronary intervention, even smaller amounts of abciximab than standard dose, injected locally, could achieve a rapid thrombus resolution and clinical improvement without concomitant differences in hemorrhagic complications

Condition or Disease	Intervention/Treatment	Phase
Coronary Disease Myocardial Infarction	Drug: abciximab	Phase 4

Detailed Description

Patients both with acute myocardial infarction and unstable angina are prone to extensive intracoronary thrombosis, leading to acute deterioration during percutaneous coronary intervention or thrombosis of the device despite therapy. Intracoronary use of abciximab has reported favourable results. We randomly assigned 84 patients to intracoronary half abciximab bolus (group A) and to standard regimen (group B).